Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis-Reference-Cited by-同舟云学术

Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis

Published:2016-08-19 Issue:10 Volume:35 Page:2615-2618
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Giraud C.,Tatar Z.,Soubrier M.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-016-3379-6.pdf

Reference27 articles.

1. Kremer JM, Blanco R, Brzosko M, et al. (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63:609–621

2. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580–1584

3. Jones G, Sebba A, Gu J, Lowenstein MB, et al. (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the ambition study. Ann Rheum Dis 69:88–96

4. Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA (2014) Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol 41:858–861

5. Marotte H, Paintaud G, Watier H, Miossec P (2008) Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis 67:893–894

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine;Frontiers in Immunology;2022-01-10

2. Association of Parvovirus B19 with Rheumatic Diseases;Journal of Clinical Rheumatology and Immunology;2021-11-15

3. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies;Clinical Microbiology Reviews;2020-06-17

4. Biotherapies-induced neutropenia in autoimmune and auto-inflammatory disorders and other orphan diseases;Expert Opinion on Orphan Drugs;2019-09-02

5. State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies;Journal of Clinical Medicine;2019-09-01